**MINUTES**

**CPIC CONFERENCE CALL**

DATE: August 6, 2015

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link after each conference call. |
| Term Standardization project update | Kelly presented the results from the 4th round of the Term Standardization Project (<https://www.pharmgkb.org/page/cpicTermProject>). We reached consensus (>70%) for all categories except for the drug metabolizing enzyme phenotype. We plan to either have one more round of survey or use an expert panel approach to reach consensus for these terms. | Kelly will continue to follow-up with progress. |
| CPIC R24 grant | Mary announced that CPIC has received NIH funding (1/2 NHGRI and ½ NIGMS) to support CPIC. As outlined in the grant proposal, we will continue to formalize interactions with external groups (e.g., ClinVar, ClinGen, DIGITizE (<http://iom.nationalacademies.org/Activities/Research/GenomicBasedResearch/Innovation-Collaboratives/EHR.aspx>),etc.) and formalize processes for using feedback to improve CPIC. An external expert advisory committee composed of experts in pharmacogenetics and/or clinical practice guideline development will also be assembled. CPIC will develop a standalone CPIC website (independent of the PharmGKB website) that will still link to PharmGKB. We will continue to ask CPIC membership for ideas and feedback. | Mary/Teri will continue to update CPIC membership of any changes. |
| Update regarding ACMG and incorporation of PGx variants | Teri met with co-chairs of the ACMG Secondary Findings Working Group and they are interested in CPIC working with them to nominate PGx genes. (Please see <https://www.acmg.net/secondaryfindings>). There is now a process to expand the list of ACMG genes to include pharmacogenetic genes. CPIC/PharmGKB leadership worked to edit the nomination process for Pgx genes. To test the submission procedure, we submitted three variants for inclusion and received preliminary feedback from the ACMG Secondary Findings Working group with some of their concerns, including challenges that 1) Pgx gene variants are so common that they might cause additional burden to clinicians; 2) a perceived lack of immediate actionability due to sporadic nature of drug use; 3) and concerns related to lack of effective Electronic Health Records in most institutions. CPIC/PharmGKB leadership responded to the committee’s concerns. One compromise being considered is to have separate categories for disease-causing mutations versus Pgx genes. | Teri will follow-up with progress. |
| CPIC Informatics Update | Kelly updated the group on the last CPIC informatics working group call. This group continues to contribute to the Term Standardization Project and is planning the next steps for this project. On the last call, we discussed our interactions with ClinGen and the process for submission of the final terms to LOINC. The group also discussed a plan for a two gene recommendation (i.e. TCA guideline) as our current figures and tables will need to be modified for this approach. | James/Michelle/Bob will continue to follow-up with progress. |